Corporate ActionJul 27, 2026, 05:11 PM
Co-Diagnostics Removes ATM Share Sale Limit with Maxim Group
AI Summary
Co-Diagnostics, Inc. amended its Equity Distribution Agreement with Maxim Group LLC, removing the fixed aggregate dollar limitation on sales of its common stock. This change allows the company to sell shares up to the amount registered under its effective shelf registration statement. Additionally, the company agreed to extend a non-issuance period with existing investors until August 14, 2026.
Key Highlights
- Co-Diagnostics amended its Equity Distribution Agreement with Maxim Group LLC on July 27, 2026.
- The amendment removed the fixed aggregate dollar limitation on sales of common stock.
- Future share sales are now limited solely by the amount registered under the effective registration statement.
- The company filed a related prospectus supplement dated July 27, 2026.
- Co-Diagnostics extended a non-issuance period with investors to August 14, 2026.
Price Impact
More from CODX